Lexicon Pharma (LXRX) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.42 -4.05%
EPS Growth %: -50.0%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -50.0%
Financial Fact:
Interest expense: -1.65M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $1.25 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Freedom Broker Upgrades Garrett Motion (GTX) to Buy
- Top oil & gas exploration stocks, according to Mizuho
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
